The COVID-19 pandemic brought an enormous urgency to the life sciences sector. Companies vied for suitable treatments and in less than a year, COVID-19 vaccines were developed. This demonstrated clearly that the sector could move at speed when necessary. Though vaccines were supported by regulators, inefficiencies in vaccine and drug development were exposed.
Author
Decentralizing clinical trials: how COVID-19 has changed drug development